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Abstract
Whether influenza vaccination influences the severity of illness in cases of clinical failure in solid organ transplant (SOT) recipients
receiving influenza vaccine has not been extensively studied. Our goal was to evaluate the frequency of influenza vaccination among
SOT recipients with influenza disease and its impact on the illness severity during the 2010–2011 season. Adult SOT recipients with
confirmed influenza infection were included from December 2010 to April 2011. Follow-up data were recorded and antibody titres
were determined using a microneutralization assay. Sixty-four SOT recipients were included in the study, ten (15.6%) with severe dis-
ease, requiring admission to intensive care units, of whom four (6.3%) died. In all, 34 (53.1%) received the 2010–2011 seasonal influenza
vaccine and 32 (50.0%) received the 2009-H1N1 pandemic vaccine, and none had detectable antibodies against influenza at the time of
diagnosis of influenza infection. Twenty-three (67.6%) of the patients that received the vaccine required hospital admission and pre-
sented less dyspnoea (10, 29.4% versus 14 (50.0%), p 0.09) and pneumonia (8, 23.8% versus 15, 50.0%, p 0.03, relative risk 0.3, 95% CI
0.1–0.9) than unvaccinated patients, with relative risk reductions of 60% and 70%, respectively. Although influenza vaccination confers
protection on SOT recipients against developing influenza pneumonia, the rate of clinical failure is still high. New strategies to improve
influenza immunization are needed for this group of patients.
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Introduction
Respiratory infections, especially influenza infections, are a
major cause of morbidity and mortality in solid organ transplant
(SOT) recipients [1]. Influenza infections cause complications
including primary and secondary viral pneumonia [1,2] and pro-
longed periods of viral shedding [3]. Since the last influenza
virus A (H1N1) pandemic in 2009, an increased knowledge of
influenza infection has confirmed the severity of the infection in
this population. Different studies in SOT recipients have
reported a rate of mortality associated with influenza infection
ranging from 4% to 8%, with severe cases or complications in
12–20% of cases [1,4].
Annual vaccination for seasonal influenza is the most effec-
tive strategy for reducing the incidence and complications of
influenza infection, which have been shown to reduce
mortality and decrease the risk of graft loss in the transplant
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population as observed in a retrospective study of 51 730
adults transplanted when vaccinated within the first year
after transplantation [5]. However, the response to influenza
vaccination in the transplant setting is discordant, with lower
efficacy than in the general population with a seroprotection
rate that varies between 15% and 90% [6–16]. Suboptimal
vaccination response may be partly a result of the incom-
plete protection against influenza reported for vaccination in
high-risk individuals [17]. Older individuals appear to be at
particular risk for vaccine failure, perhaps as a result of
immune senescence [18].
Clinical failure of influenza vaccination in SOT recipients
has not been extensively studied. A retrospective cohort
study, which evaluated the clinical effectiveness of the 2009-
adjuvanted pandemic influenza vaccine in 168 patients,
showed that 96.4% were seroprotected [19]. In a multicen-
tre study mentioned previously, we demonstrated a rate of
clinical failure after receiving one dose of the pandemic vac-
cine of 1.1% [20]. However, there are no clinical studies that
evaluate the impact of the antecedent of influenza vaccina-
tion in the SOT recipients with influenza disease. Hence, the
goal of the present study was to evaluate the frequency of
non-adjuvanted 2010–2011 seasonal influenza vaccination
among SOT recipients with influenza disease and its reper-
cussion on the illness severity.
Materials and Methods
Subjects and study design
This prospective cohort observational study was conducted
at eight teaching hospitals belonging to the Spanish Network
for Research in Infectious Diseases (REIPI). All SOT recipi-
ents older than 16 years diagnosed with confirmed influenza
virus infection who attended hospital from December 2010
to April 2011 were included. Cases were detected on a daily
basis by reviewing the microbiological reports. A confirmed
case was defined as the presence of influenza-like illness with
laboratory-confirmed influenza infection. The study was
approved by the local ethics committee and informed con-
sents were obtained from all subjects. This study was carried
out considering the current legislation, the ethical regulations
of the Helsinki Declaration and the guidelines on good clini-
cal laboratory practice.
Clinical parameters
Patients were advised to seek care at the hospital in cases of
respiratory symptoms. One or more of the investigators in
each participating hospital evaluated and followed patients
after influenza diagnosis, and clinical data were recorded in a
standardized, computer-assisted protocol. Data were col-
lected on demographic characteristics, co-morbidities, body
mass index, type of transplant and immunosuppressive ther-
apy, time since transplantation, previous history of vaccina-
tion, clinical signs and symptoms, biochemical analysis, chest
X-ray findings, antiviral and antibacterial therapy, concomi-
tant and secondary bacterial infections, time to clinical stabil-
ity, and outcomes, including mortality. A follow-up visit took
place 28 days after diagnosis. Completed protocols were
revised by a senior investigator before the final validation.
Cases of influenza A (2009-H1N1, H3N2) infection were
diagnosed by RT-PCR (Inf A/H1N1 Detection; Roche, Mann-
heim, Germany) and influenza B virus was detected using the
Detection Set, Lightcycler 2.0 system, (Roche; for details, see
Supplementary material, Data S1). Other respiratory viral
infections were tested by multiplex-PCR (mPCR; Seeplex-
RV15ACE Detection kit, Seegene Inc., Seoul, Korea) that
detects 15 respiratory viruses (human metapneumovirus,
adenovirus, coronavirus 229E/NL63, coronavirus-OC43/
HKU1, parainfluenza 1–3, rhinovirus A/B/C, respiratory syn-
cytial A-B and influenza A-B, enterovirus, bocavirus 1/2/3/4).
Concomitant and secondary non-viral infection (co-infection)
was considered if a bacterium or fungus was isolated from at
least one of the following samples: blood, pleural fluid, spu-
tum culture, bronchial aspirate, bronchoalveolar lavage, pro-
tected specimen brush, transbronchial biopsy or in cases
with positive urinary antigen tests for Streptococcus pneumo-
niae and Legionella pneumophila serogroup 1. Hypogamma-
globulinaemia was defined as IgG levels under 700 mg/dL.
Pneumonia was defined by the presence of clinical symptoms
(fever, dyspnoea, cough and expectoration) and a new pul-
monary infiltrate in the chest X-ray for which other non-
infectious causes were excluded. Severe disease was defined
as requiring admission to intensive care (respiratory insuffi-
ciency, septic shock and severe sepsis), mortality during influ-
enza illness or allograft rejection. Early antiviral therapy was
defined as the administration of antiviral agents active against
2009 influenza A/H1N1 or B within the 48 h after the onset
of symptoms.
Vaccination
Recipients of SOT received the influenza seasonal vaccine at
their healthcare centres as part of the national vaccination
recommendations [21]. Vaccinated patients were given one
dose of the trivalent non-adjuvanted vaccine for the 2010–
2011 influenza season (Gripavac; Sanofi-Pasteur MSD,
Madrid, Spain). Each dose of vaccine contained the strains
included in the trivalent seasonal influenza 2010–2011 vac-
cine: A/California/7/2009(H1N1) (2009-H1N1 strain), A/
Perth/16/2009(H3N2) (H3N2 strain) and B/Brisbane/60/
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2008-like (B strain). Patients were considered to be vacci-
nated against influenza viruses if the vaccine was adminis-
tered at least 6 weeks before influenza infection.
Microneutralization assay
Antibody titres for the influenza 2009-H1N1 strain were deter-
mined using a microneutralization assay as previously described
[20], (for details, see Supplementary material, Data S1).
Statistical analysis
The results were analysed using the statistical software pack-
age (SPSS, version 15.0; SPSS Inc, Chicago, IL). A descriptive
statistical analysis was performed. All proportions were cal-
culated as percentages of the patients with available data and
median and interquartile range (IQR) for continuous vari-
ables. We identified clinical manifestations and risk factors of
severe disease in all SOT recipients with influenza infection
and we measured the primary effectiveness of influenza vac-
cination in reducing pneumonia or severe disease incidence
by comparing the proportions of these between vaccinated
and unvaccinated patients in the follow-up cohort, which we
calculated as (1 – relative risk) · 100. To detect significant
differences between groups, we used the chi-square test or
Fisher exact test for categorical variables and the t test,
Mann–Whitney U test and Wilcoxon test for continuous
variables, when appropriate. For the multivariate analysis,
logistic regression was used for factors influencing the risk of
pneumonia. The relative risks (RR) and 95% CI of geometric
mean titres (GMT) were calculated by taking the exponent
of natural logarithm of the mean and 95% CI. Statistical sig-
nificance was established at a = 0.05. All reported p values
are two-tailed.
Results
A total of 64 SOT recipients were included, of those, 47
(73.4%) patients required hospital admission. Types of trans-
plant were 32 (50.0%) kidney, 14 (21.9%) liver, 14 (21.9%)
heart and four (6.3%) lung with a median time from trans-
plantation of 3.8 years (1.7–8.6 years). In one vaccinated
heart transplant patient, influenza occurred 12 days after
transplant. Most patients (59, 92.2%) were diagnosed with
influenza A H1N1 (2009) virus and only five cases (7.8%)
were diagnosed with influenza B virus infection.
The median age was 59 years (48.2–65.0 years) and 44
(68.8%) were men. Fifty SOT recipients (78.1%) had comor-
bid conditions other than transplantation, with high frequen-
cies of chronic kidney and heart disease (29, 45.3% and 22,
34.4%, respectively). The most common immunosuppressive
drugs were tacrolimus (38, 59.4%), mycophenolate mophetil
(50, 78.1%) and corticosteroids (41, 64.1%) in a triple com-
bined therapy. Thirty-four (53.1%) patients received the
2010–2011 seasonal influenza vaccine more than 5 weeks
before infection and 32 (50.0%) had received the pandemic
influenza A H1N1 (2009) vaccine the previous season
(Table 1).
Clinical manifestations and outcomes: risk factors of severe
disease
The median time from symptom onset to influenza diagnosis
was 4.5 days (IQR 2.0–10.0) with the most common manifes-
tations being cough (56, 87.5%) and fever (48, 48.4%;
Table 2). Ten (15.6%) patients had severe disease and pneu-
monia, requiring admission to intensive care and four (6.3%)
of them died. No other respiratory viruses were detected in
the samples. Bacterial co-infection was more common in
patients with severe disease (3, 30% versus 4, 7.4%, p 0.03,
RR 3.4, 95% CI 1.1–10.5) with S. pneumoniae (two cases) and
Aspergillus spp. (one case) in patients with severe disease ver-
sus S. pneumoniae (one case), Pseudomonas aeruginosa (two
cases) and Aspergillus spp. and Rhizopus spp. (one case) in
patients with non-severe disease.
Other factors associated with severe disease were:
chronic heart disease (7, 70% versus 15, 24.8%, p 0.01, RR
4.5, 95% CI 1.3–15.6), chronic pulmonary disease (5, 50%
versus 11, 20.4%, p 0.04, RR 3, 95% CI 1–9), dyspnoea (7,
77.8% versus 17, 32.1, p 0.009, RR 5.5, 95% CI 1.2–24.5) and
pneumonia (10, 100% versus 13, 24.1%, p <0.001; Table 3).
Patients with severe disease initiated antiviral therapy at a
median of 10.5 days (3.8–15.8 days) and patients with non-
severe disease at a median of 4 days (3–11 days) (p 0.21).
Two patients with mild disease (3.1%) did not receive osel-
tamivir therapy, having favourable outcome. Median time of
antiviral therapy was 10 days (6.5–14.0 days) versus 5 days
(5.0–7.0 days; p 0.002) in severe and mild cases, respectively.
Immunological response to vaccination and clinical
repercussions
In 44 (68.7%) patients antibody titres against influenza A
H1N1 (2009) or influenza B virus were measured at the time
of detecting the infection and 4 weeks later. At the moment
of influenza infection none of the patients, including 34
patients who had received 2010–2011 seasonal influenza vac-
cine, had detectable antibody titres against influenza viruses.
At a median of 28 days after the influenza infection symptom
onset, 20 (45.5%) patients had developed antibody titres with
a GMT post-infection of 144.2 (95% CI 113.2–183.6).
Seroprotection after influenza infection happened more
frequently in patients with pneumonia (9, 45.0% versus 2,
CMI Perez-Romero et al. Influenza vaccination in SOT recipients E535
ª2012 The Authors
Clinical Microbiology and Infection ª2012 European Society of Clinical Microbiology and Infectious Diseases, CMI, 18, E533–E540
8.3%, RR 2.4, 95% CI 1.4–4.3, p 0.005) and severe disease (5,
25.0% versus 0, 0.0%, RR 2.6, 95% CI 1.7–3.6, p 0.009). In
addition, GMT post-infection were also higher in cases of
pneumonia (63.6, 95% CI 15.3–264.5 versus 5.1, 95% CI 2.2–
11.7 p 0.007) and in severe disease (211.1, 95% CI 97.8–
455.9 versus 6.5, 95% CI 2.9–14.0; p 0.001). Seroprotection
rate or GMT post-infection were not related with receiving
2010–2011 seasonal influenza vaccine (55.0% versus 58.3%;
p 0.82 and 8.6, 95% CI 3.1–24.0 versus 11.1, 95% CI 3.1–
39.4; p 0.65, respectively). In two of the patients who died
(4.5%) antibody titres after the infection could be
determined with a GMT post-infection of 160 and 320,
respectively.
Twenty-three (67.6%) of the 34 patients that received the
2010–2011 seasonal influenza vaccine required hospital
admission. Vaccinated patients less frequently experienced
TABLE 1. Patient characteristics according to the status of the 2010–2011 seasonal influenza vaccination
Baseline characteristics Total (n = 64) Vaccinated (n = 34) Unvaccinated (n = 30) p
Sex
Male 44 (68.8%) 24 (70.6%) 20 (60.7%) 0.73
Age (median, IQR) 59 (48.2–65.0) 60.5 (48.7–65.7) 58 (48–65) 0.44
£65 years 47 (73.9%) 25 (73.5%) 22 (73.3%) 0.98
>65 years 17 (26.6%) 9 (26.5%) 8 (26.7%)
Type of transplant
Kidney 32 (50%) 26 (47.1%) 16 (53.3%) 0.21
Liver 14 (21.9%) 5 (14.7%) 9 (30%)
Heart 14 (21.9%) 10 (29.4%) 4 (13.3%)
Lung 4 (6.3%) 3 (8.8%) 1 (3.3%)
Comorbidities 50 (78.1%) 27 (79.4%) 23 (76.7%) 0.79
Chronic pulmonary disease 16 (25%) 9 (26.5%) 7 (23.3%) 0.77
Chronic heart disease 22 (34.4%) 12 (35.3%) 10 (33.3%) 0.86
Diabetes mellitus 15 (23.4%) 12 (35.3%) 3 (10%) 0.01
Chronic kidney disease 29 (45.3%) 15 (44.1%) 14 (46.7%) 0.83
Chronic liver disease 8 (12.5%) 4 (11.8%) 4 (13.3%) 0.85
Influenza vaccines
2010–2011 vaccine 34 (53.1%)
2009–2010 vaccine 38 (59.4%) 31 (93.3%) 7 (28%) <0.001
2009 H1N1 32 (50%) 27 (87.1%) 5 (20%) <0.001
Hypogammaglobulinaemia 10 (15.6%) 5 (14.7%) 5 (17.9%) 0.73
Immunosuppressive therapy
Cyclosporine 17 (26.6%) 9 (26.5%) 8 (26.7%) 0.98
Tacrolimus 38 (59.4%) 19 (55.9%) 19 (63.3%) 0.54
MMF 50 (78.1%) 23 (67.6%) 27 (90%) 0.03
mTOR inhibitors 12 (18.8%) 9 (26.5%) 3 (10%) 0.09
Corticosteroids 41 (64.1%) 20 (58.8%) 21 (70%) 0.35
Monoclonal antibody induction therapy 5 (7.8%) 2 (5.9%) 3 (10%) 0.54
IQR, interquartile range; MMF, mycophenolate mofetil; mTOR, mammalian target of rapamycin.
Parameters were compared statistically by Chi-square test, p £0.05 was considered significantly different. The Mann–Whitney U test was used for continuous variables.
TABLE 2. Clinical characteristics and outcomes in vaccinated versus unvaccinated patients
Total (n = 64) Vaccinated (n = 34) Unvaccinated (n = 30) p
Hospitalization 47 (73.4%) 23 (67.6%) 24 (80%) 0.26
Clinical symptoms
Rhinorrhoea 30 (46.9%) 19 (55.9%) 11 (39.3%) 0.19
Cough 56 (87.5%) 29 (85.3%) 27 (96.4%) 0.14
Fever 31 (48.4%) 15 (44.1%) 16 (57.1%) 0.30
Dyspnoea 24 (37.5%) 10 (29.4%) 14 (50%) 0.09
Diarrhoea 13 (20.3%) 10 (29.4%) 3 (10.7%) 0.07
Myalgia-arthralgia 20 (31.3%) 12 (35.3%) 8 (28.6%) 0.57
Laboratory and radiological findings
Leucopenia (<4000/mm) 10 (15.6%) 7 (20.6%) 3 (10.3%) 0.26
Leucocytosis (>12 000/mm) 6 (9.4%) 3 (8.8%) 3 (10.3%) 0.83
Neutropenia (<500/lL) 3 (4.7%) 2 (5.9%) 1 (3.6%) 0.67
Lymphopenia (<1500/lL) 47 (73.4%) 21 (61.8%) 26 (89.7%) 0.01
Anaemia (haematocrit <36%) 34 (53.1%) 16 (47.1%) 18 (62.1%) 0.23
Thrombocytopenia (<150 · 103/lL) 20 (31.3%) 11 (32.4%) 9 (31%) 0.91
Pneumonia 23 (35.6%) 8 (23.5%) 15 (50%) 0.02
Bacterial co-infection 7 (10.9%) 4 (11.8%) 3 (10%) 0.82
Clinical outcomes
Severe disease 10 (15.6%) 4 (11.8%) 6 (20%) 0.36
ICU admission 10 (15.6%) 4 (11.8%) 6 (20%) 0.36
Death 4 (6.3%) 2 (6.7%) 2 (5.9%) 0.89
Length of hospital stay (median, IQR) 12 (7.0–29.0) 8 (5.0–18.0) 12.5 (8.0–31.0) 0.03
ICU, intensive-care unit admission; IQR, interquartile range.
Parameters were compared statistically by Chi-square test, p £0.05 was considered significantly different. The Mann–Whitney U test was used for continuous variables.
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dyspnoea (10, 29.4% versus 14, 50.0%, p 0.09) with a relative
risk reduction of 60.0% (95% CI 37.1–88.3%) and pneumonia
(8, 23.8% versus 15, 50.0%, p 0.03, RR 0.3, 95% CI 0.1–0.9)
with a relative risk reduction of pneumonia of 70% (95% CI
42.2–97.6%). Another factor associated with pneumonia was
chronic pulmonary disease. In the multivariate analysis,
receiving the influenza vaccine 2010–2011 was the only mod-
ifiable independent associated factor for pneumonia (OR
0.15, 95% CI 0.03–0.62, p 0.009; Table 4).
Four vaccinated patients and six unvaccinated had severe
disease (11.8% versus 20.0%, p 0.36), all of them with pneu-
monia and requiring admission to intensive care. Two
patients in each group died (2, 5.9% versus 2, 6.7%, p 0.89).
The proportion of patients receiving early antiviral therapy
was similar in vaccinated and unvaccinated patients (23.3%
versus 18.5%; p 0.65). The median length of hospital stay was
different: 8 days (5.0–18.0 days) in vaccinated patients, and
12.5 days (8.0–31.0) in unvaccinated patients, p 0.03;
Tables 2 and 3).
Discussion
Our results show that the antecedent of seasonal vaccination
must not preclude the consideration of influenza infection in
SOT recipients with respiratory symptoms in epidemic peri-
ods. Hence, more than half of patients with influenza illness
had received 2010–2011 influenza vaccination, and most of
them required hospital admission, with a severe disease
occurring in 12% of them. However, influenza vaccination
was associated with a lower incidence of pneumonia and
shorter length of hospital stay.
Since the last pandemic it has been demonstrated that
influenza infection in SOT recipients is associated with a
higher mortality rate than in the general population [1,4].
The mortality of influenza infection in our cohort (6%) was
associated with having bacterial co-infections at the moment
of initiating antiviral treatment and with other prognostic fac-
tors previously described such as the presence of comorbidi-
ties (chronic disease), time of initiating oseltamivir treatment,
developing dyspnoea or pneumonia, among others [22–24].
Administration of the annual influenza vaccine is currently
the most effective prevention strategy for influenza infection
in SOT recipients. Although some studies have shown similar
responses to the general population in renal [16] and liver
[9] transplant recipients, most of the studies clearly suggest
a reduced immune response in kidney [7,10,14,15], liver
[8,25] and heart [6,8] recipients. However, to our knowl-
edge this is the first study to analyse the clinical failure of
the influenza vaccine in a cohort of SOT recipients with
influenza illness and the role of vaccination on the clinical
manifestation of influenza infection in this population.
The present study demonstrates a high rate of 2010–2011
seasonal influenza vaccination among SOT recipients with
influenza. This is especially relevant, as influenza infection
must not be ruled out in influenza-vaccinated SOT recipients
with respiratory symptoms or pneumonia in pandemic or
epidemic periods. A high index of suspicion and an early
diagnosis is mandatory, given the fact that, as previously
reported, we found that time from onset of symptoms to
initiating oseltamivir therapy was associated with the severity
of the illness. Our findings are in agreement with previous
studies characterizing the immunological response to influ-
enza vaccine in SOT recipients. Although some of these
studies have shown similar responses in renal [16] and liver
[9] transplant recipients compared with that of the general
population, most of them showed a reduced humoral
immune response in renal [7,10,14,15], liver [8,25,26], lung
[27] and cardiac [6,8] transplant recipients, with a seropro-
tection rate that varies between 15% and 90% [6–16] and a
TABLE 3. Characteristics of patients with severe disease
Severe
disease (n = 10)
Non-severe
disease (n = 54)
p
Age
£65 years 7 (70%) 40 (74.1%) 0.78
>65 years 3 (30%) 14 (26%)
Time since
transplantation (years)
6.1 (0.19–16.8) 3.9 (0.07–22.9) 0.41
Type of transplant
Kidney 6 (60%) 26 (48.1%) 0.73
Liver 2 (20%) 12 (22.2%)
Heart 1 (10%) 13 (24.1%)
Lung 1 (10) 8 (15.4%)
Immunosuppressive
therapy
Cyclosporine 2 (20%) 15 (27.8%) 0.60
Tacrolimus 7 (70%) 31 (57.4%) 0.45
MMF 9 (90%) 41 (75.9%) 0.32
mTOR inhibitors 1 (10%) 11 (20.4%) 0.44
Corticosteroids 8 (80%) 33 (61.1%) 0.25
Monoclonal antibody
induction therapy
0 (0%) 5 (9.3%) 0.31
2010–2011 seasonal
influenza vaccination
4 (40%) 30 (55.6%) 0.36
Hypogammaglobulinaemia 2 (20%) 8 (15.4%) 0.71
Comorbidities 9 (90%) 41 (75.4%) 0.32
Chronic pulmonary disease 5 (50%) 11 (20.4%) 0.04
Diabetes 0 (0%) 15 (27.8%) 0.06
Chronic heart disease 7 (70%) 15 (27.8%) 0.01
Chronic renal failure 6 (60%) 23 (42.6%) 0.31
Chronic liver failure 3 (30%) 5 (9.3) 0.07
Clinical variables
Rhinorrhoea 2 (22.2%) 28 (52.8%) 0.09
Cough 9 (90%) 47 (87%) 0.28
Dyspnoea 7 (77.8%) 17 (32.1%) 0.009
Diarrhoea 2 (22.2%) 11 (20.8) 0.92
Myalgia-arthralgia 1 (10%) 19 (35.2%) 0.14
Pneumonia 10 (100%) 13 (24.1%) <0.001
Time to initiation
of treatment
10.5 (3.8–15.8) 4 (3.0–11.0) 0.21
Bacterial co-infection 3 (30%) 4 (7.4%) 0.03
MMF, mycophenolate mofetil; mTOR, mammalian target of rapamycin.
Parameters were compared statistically by Chi-square test, p £0.05 was consid-
ered significantly different. The Mann–Whitney U test was used for continuous
variables.
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lower seroprotection rate after vaccination of 78% com-
pared with healthy subjects [7].
However, our results suggest that receiving the influenza
vaccine confers protection against the development of pneu-
monia in patients with influenza infection because it was
associated with a decreased risk of developing pneumonia
and shorter hospital stay. Attenuation of disease severity has
been described for other vaccines such as the 23-valent poly-
saccharide vaccine against S. pneumoniae that was tested in
the elderly, where vaccination was associated with a reduc-
tion of risk of death due to pneumonia complications
[28,29]. Limited data of a similar effect are available for non-
replicating influenza vaccines [30,31], but no studies have
been performed in transplant recipients. Reduction in illness
severity, even among those who are not protected against
infection, would enhance the population health benefits of
this vaccine.
In the present study, nearly half of the patients had not
received influenza vaccination. Vaccination is indicated
beyond the second month of transplant in all protocols at all
participating centres and this percentage does not represent
the proportion of patients that receive vaccination in our
SOT recipient population. Nevertheless, an effort should be
made to increase the number of patients and relatives
receiving influenza vaccination.
None of the patients had antibody titres in response to
vaccination at the onset of illness and less than half of them
had seroconverted 4 weeks after influenza diagnosis. How-
ever, patients that developed severe symptoms of influenza
infection presented higher antibody titres at convalescence,
probably as a result of the exposure to an increased influ-
enza viral load triggering a stronger immune response.
Our study has several limitations. First, the number of
patients included in the study may be underpowered to dem-
onstrate the association of the mortality rate and previous
vaccination. In addition, although all patients were advised to
seek care at the hospital if they had respiratory tract infec-
tion symptoms, it is possible that some patients with mild
influenza infection did not attend the hospital. However, all
severe cases of influenza were included in the study. As the
objective of the study was not to evaluate the clinical efficacy
of the vaccine, but to determine vaccination frequency
among clinical cases of influenza, the loss of some mild cases
does not invalidate our results, which show that vaccination
failed in half of SOT recipients with severe influenza. Finally,
given the association of severity and seroconversion, the epi-
sode of respiratory illness could be caused by other micro-
organisms and the detection of influenza virus might be
related to an asymptomatic colonization. However, although
investigated, no other viral co-infections were detected in
these patients and the positive predictive value of respiratory
symptoms during the influenza epidemic period is very high
[32]. We therefore think that these episodes corresponded
to true influenza infections.
In conclusion, the response of SOT recipients to influenza
vaccine is not optimal with a high rate of failure among hos-
pital-treated influenza cases, demonstrating that new strate-
gies to improve influenza immunization are needed in this
patient subgroup. However, influenza vaccination may confer
protection against the development of influenza pneumonia.
Further studies are warranted to validate these findings in a
larger cohort and to evaluate its impact on other outcome
endpoints, such as mortality.
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